Logo image of ALT

ALTIMMUNE INC (ALT) Stock Fundamental Analysis

NASDAQ:ALT - Nasdaq - US02155H2004 - Common Stock - Currency: USD

6.955  +0.07 (+0.94%)

Fundamental Rating

3

ALT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 557 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ALT as it has an excellent financial health rating, but there are worries on the profitability. ALT is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ALT has reported negative net income.
In the past year ALT has reported a negative cash flow from operations.
In the past 5 years ALT always reported negative net income.
ALT had a negative operating cash flow in each of the past 5 years.
ALT Yearly Net Income VS EBIT VS OCF VS FCFALT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -57.38%, ALT perfoms like the industry average, outperforming 43.63% of the companies in the same industry.
ALT has a Return On Equity (-63.48%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -57.38%
ROE -63.48%
ROIC N/A
ROA(3y)-50.39%
ROA(5y)-43.11%
ROE(3y)-56.08%
ROE(5y)-47.74%
ROIC(3y)N/A
ROIC(5y)N/A
ALT Yearly ROA, ROE, ROICALT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

ALT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALT Yearly Profit, Operating, Gross MarginsALT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200K -400K

More info and screens

8

2. Health

2.1 Basic Checks

ALT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALT has more shares outstanding
The number of shares outstanding for ALT has been increased compared to 5 years ago.
There is no outstanding debt for ALT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ALT Yearly Shares OutstandingALT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ALT Yearly Total Debt VS Total AssetsALT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

ALT has an Altman-Z score of 16.08. This indicates that ALT is financially healthy and has little risk of bankruptcy at the moment.
ALT has a better Altman-Z score (16.08) than 92.10% of its industry peers.
There is no outstanding debt for ALT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 16.08
ROIC/WACCN/A
WACC9.1%
ALT Yearly LT Debt VS Equity VS FCFALT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

ALT has a Current Ratio of 15.85. This indicates that ALT is financially healthy and has no problem in meeting its short term obligations.
ALT has a better Current ratio (15.85) than 89.05% of its industry peers.
A Quick Ratio of 15.85 indicates that ALT has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 15.85, ALT belongs to the top of the industry, outperforming 89.05% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 15.85
Quick Ratio 15.85
ALT Yearly Current Assets VS Current LiabilitesALT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

ALT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.70%, which is quite good.
Looking at the last year, ALT shows a very negative growth in Revenue. The Revenue has decreased by -95.15% in the last year.
The Revenue for ALT have been decreasing by -67.82% on average. This is quite bad
EPS 1Y (TTM)8.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.53%
Revenue 1Y (TTM)-95.15%
Revenue growth 3Y-83.45%
Revenue growth 5Y-67.82%
Sales Q2Q%0%

3.2 Future

Based on estimates for the next years, ALT will show a very strong growth in Earnings Per Share. The EPS will grow by 37.54% on average per year.
Based on estimates for the next years, ALT will show a very strong growth in Revenue. The Revenue will grow by 871.94% on average per year.
EPS Next Y2.14%
EPS Next 2Y-10.62%
EPS Next 3Y-0.73%
EPS Next 5Y37.54%
Revenue Next Year-57.2%
Revenue Next 2Y8065.01%
Revenue Next 3Y1778.25%
Revenue Next 5Y871.94%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ALT Yearly Revenue VS EstimatesALT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 500M 1B
ALT Yearly EPS VS EstimatesALT Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 20 -20 -40 -60 -80

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ALT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ALT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALT Price Earnings VS Forward Price EarningsALT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALT Per share dataALT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.62%
EPS Next 3Y-0.73%

More info and screens

0

5. Dividend

5.1 Amount

ALT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALTIMMUNE INC

NASDAQ:ALT (6/18/2025, 12:53:09 PM)

6.955

+0.07 (+0.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners47.88%
Inst Owner Change-6.06%
Ins Owners0.74%
Ins Owner Change1.61%
Market Cap564.12M
Analysts81.67
Price Target22.29 (220.49%)
Short Float %27.31%
Short Ratio8.24
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.66%
Min EPS beat(2)0.21%
Max EPS beat(2)29.11%
EPS beat(4)3
Avg EPS beat(4)9.54%
Min EPS beat(4)-1.62%
Max EPS beat(4)29.11%
EPS beat(8)7
Avg EPS beat(8)14%
EPS beat(12)11
Avg EPS beat(12)13.57%
EPS beat(16)13
Avg EPS beat(16)4.98%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)4.89%
EPS NQ rev (3m)13.44%
EPS NY rev (1m)0%
EPS NY rev (3m)11.58%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-99.74%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 28206
P/FCF N/A
P/OCF N/A
P/B 3.97
P/tB 3.97
EV/EBITDA N/A
EPS(TTM)-1.26
EYN/A
EPS(NY)-1.64
Fwd EYN/A
FCF(TTM)-0.99
FCFYN/A
OCF(TTM)-0.99
OCFYN/A
SpS0
BVpS1.75
TBVpS1.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -57.38%
ROE -63.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-50.39%
ROA(5y)-43.11%
ROE(3y)-56.08%
ROE(5y)-47.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.85
Quick Ratio 15.85
Altman-Z 16.08
F-Score2
WACC9.1%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.53%
EPS Next Y2.14%
EPS Next 2Y-10.62%
EPS Next 3Y-0.73%
EPS Next 5Y37.54%
Revenue 1Y (TTM)-95.15%
Revenue growth 3Y-83.45%
Revenue growth 5Y-67.82%
Sales Q2Q%0%
Revenue Next Year-57.2%
Revenue Next 2Y8065.01%
Revenue Next 3Y1778.25%
Revenue Next 5Y871.94%
EBIT growth 1Y-10.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-4.85%
EBIT Next 3Y-15.54%
EBIT Next 5Y12.97%
FCF growth 1Y-17.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-17.32%
OCF growth 3YN/A
OCF growth 5YN/A